Navigation Links
PharmaVentures Appoints Andy Smith as Head of Corporate Finance
Date:10/4/2011

OXFORD, England, October 4, 2011 /PRNewswire/ --

PharmaVentures today announced the appointment of Andy Smith as Head of Corporate Finance to significantly enhance Pharmaventures' advisory capabilities and offerings to the global healthcare and investment communities.

Fintan Walton, PhD, PharmaVentures' Chief Executive Office says "We are delighted to welcome Andy to PharmaVentures.  He brings a wealth of investment management experience and has also worked extensively across R&D and marketing in the healthcare sector. At PharmaVentures we are increasingly providing more investment bank style services to help our clients with their dealmaking and Andy's addition to PharmaVentures will therefore be of great benefit."

Andy has a PhD in molecular Biology and an MBA in International Marketing.  He has previously worked with Investment Managers 3i, Schroders Plc and AXA Framlington.  In 2007 he was awarded the techmark Technology Fund Manager of the year.  Since 2011 Andy has written a regular weekly column; Stockwatch, in Scrip and has lectured on healthcare valuations and modeling at the University of Cambridge for the last six years.

PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.


For further information
Fintan Walton, CEO
+44-1865-332733
odette.hodder@pharmaventures.com


'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
2. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
3. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
4. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
5. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
6. Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PrimeraDx Appoints Albert A. Luderer to its Board of Directors
9. Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... --> --> ... Point-Of-Care (POC) molecular diagnostics company, today announces that it has ... to be launched on the Company,s io® platform. By meeting ... is now cleared for sale within the European Union. ... the io® CT test signals a new era in ultra-rapid ...
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today that Edward Lanphier , Sangamo,s president and ... progress of Sangamo,s ZFP Therapeutic ® development programs ... 2:40 pm ET on Thursday, February 11, 2016, at ... Conference. The conference is being held in ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
Breaking Biology News(10 mins):